| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 08/16/2001 | WO2001058899A1 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase |
| 08/16/2001 | WO2001058897A1 Benzthiazoles as tnf and pde-iv inhibitors |
| 08/16/2001 | WO2001058896A1 Benzoxazole derivatives as tnf and pde iv inhibitors |
| 08/16/2001 | WO2001058895A1 Benzofuran carboxamides and their therapeutic use |
| 08/16/2001 | WO2001058893A2 Indol-3-yl derivatives and their use as integrin inhibitors |
| 08/16/2001 | WO2001058892A1 Tyrosine derivatives with anti-leukotriene activity |
| 08/16/2001 | WO2001058890A1 Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 |
| 08/16/2001 | WO2001058886A1 Dipeptide nitrile cathepsin k inhibitors |
| 08/16/2001 | WO2001058882A1 Use of pyrimidine endothelin antagonists in companion animals |
| 08/16/2001 | WO2001058881A1 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 08/16/2001 | WO2001058877A1 Interferon ω production potentiators |
| 08/16/2001 | WO2001058853A1 Dehydroamino acids |
| 08/16/2001 | WO2001058479A1 Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| 08/16/2001 | WO2001058473A1 Method of treating or inhibiting cellular injury or cell death |
| 08/16/2001 | WO2001058471A2 Novel amino acid and peptide inhibitors of staphylococcus virulence |
| 08/16/2001 | WO2001058470A2 Methods for enhancing the bioavailability of a drug |
| 08/16/2001 | WO2001058457A1 Novel uses of polyanionic polyglycosides in treating gut disorders |
| 08/16/2001 | WO2001058456A1 Polyanionic polyglycosides in the treatment of autism |
| 08/16/2001 | WO2001058455A1 Method to potentiate the therapeutic efficacy of taxane and derivatives thereof |
| 08/16/2001 | WO2001058451A1 Tamper-resistant oral opioid agonist formulations |
| 08/16/2001 | WO2001058448A1 Apoptosis inhibitor |
| 08/16/2001 | WO2001058447A1 Controlled-release compositions containing opioid agonist and antagonist |
| 08/16/2001 | WO2001058444A1 Use of cyp1b1 inhibitors for treating cancer |
| 08/16/2001 | WO2001058443A1 TNF- α INHIBITORS |
| 08/16/2001 | WO2001058441A1 Method and compositions for treating an inflammatory disease |
| 08/16/2001 | WO2001058412A2 Extracts from residues left in the production of wine |
| 08/16/2001 | WO2001058241A2 Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver |
| 08/16/2001 | WO2001051047A8 Use of fumaric acid derivatives for treating mitochondrial diseases |
| 08/16/2001 | WO2001024773B1 Liposome-entrapped dna oral vaccines |
| 08/16/2001 | WO2001023550A3 Pca3 messenger rna species in benign and malignant prostate tissues |
| 08/16/2001 | WO2001012180A3 Peroxovanadium compounds as protein tyrosine phosphatase (ptp) inhibitors: their inhibitory effects on angiogenesis, restenosis and the production of endothelins, and their stimulating effects on the immune responce |
| 08/16/2001 | WO2001011024A3 Bryostatins, bryopyrans and polyketides: compositions and methods |
| 08/16/2001 | WO2001010842A3 Melanocortin-4 receptor binding compounds and methods of use thereof |
| 08/16/2001 | WO2001010385A3 1,4-substituted 4,4-diaryl cyclohexanes |
| 08/16/2001 | WO2001010380A3 Benzanilides as potassium channel openers |
| 08/16/2001 | WO2001009173A3 Use of quinic, shikimic acids and their derivatives for preparing mannose receptor ligands |
| 08/16/2001 | WO2001007628A3 Human synthetases |
| 08/16/2001 | WO2001007595A3 Novel fibroblast growth factor and nucleic acids encoding same |
| 08/16/2001 | WO2001004354A3 Use of ras inhibitors of inhibiting muscle atrophy |
| 08/16/2001 | WO2001002569A3 Human immune response molecules |
| 08/16/2001 | WO2000078396A3 Topical ophthalmic mast cell stabilizers for treating allergic eye diseases |
| 08/16/2001 | WO2000076974A3 Oligomers and polymers of cyclic imino carboxylic acids |
| 08/16/2001 | WO2000076551A3 Method for producing an injectable medicament preparation |
| 08/16/2001 | WO2000047752A3 Macular degeneration diagnostics and therapeutics |
| 08/16/2001 | WO2000047551A3 Inhibitors of aspartyl protease |
| 08/16/2001 | US20010014741 Antiallergens, antihistamines, bronchodilator |
| 08/16/2001 | US20010014740 Method of producing heterocyclic derivatives |
| 08/16/2001 | US20010014696 Therapeutic compositions (II) |
| 08/16/2001 | US20010014691 Nervous system disorders |
| 08/16/2001 | US20010014689 Nervous system disorders |
| 08/16/2001 | US20010014683 Analgesics; side effect reduction |
| 08/16/2001 | US20010014679 Animal growth regulator; controlling cell differentiation, gene expression, glucose metabolism, protein metabolism |
| 08/16/2001 | US20010014677 Restenosis, kidney diseases, lung diseases |
| 08/16/2001 | US20010014454 Novel metal complexes |
| 08/16/2001 | US20010014357 Citrus peel extract as inhibitor of ACYL coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases |
| 08/16/2001 | US20010014342 Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained |
| 08/16/2001 | EP1123976A1 New human hepatoma-derived growth factor encoding sequence and polypeptide encoded by such dna sequence and producing method thereof |
| 08/16/2001 | EP1123935A2 3'-Fluorinated guanosine derivatives for the treatment or prophylaxis of HBV or retroviral infections |
| 08/16/2001 | EP1123926A1 Piperazine derivatives for treatment of CNS disorders |
| 08/16/2001 | EP1123922A2 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
| 08/16/2001 | EP1123717A2 Estrogen agonist/antagonist and statin containing compositions for treating osteoporosis and lowering cholesterol |
| 08/16/2001 | EP1123414A1 Antisense modulation of integrin alpha 4 expression |
| 08/16/2001 | EP1123395A2 Nucleic acids encoding osteoprotegerin-like proteins and methods of using same |
| 08/16/2001 | EP1123392A1 Prv-1 gene and the use thereof |
| 08/16/2001 | EP1123384A2 Method and compositions for improving allogeneic hematopoietic cell transplantation |
| 08/16/2001 | EP1123314A2 USE OF A CYTOKINE-PRODUCING $i(LACTOCOCCUS) STRAIN TO TREAT COLITIS |
| 08/16/2001 | EP1123309A2 Cyclic tetrapeptides and their use as histone deacetylase inhibitor |
| 08/16/2001 | EP1123308A1 Single morphic forms of known peptide metalloproteinase inhibitors |
| 08/16/2001 | EP1123297A1 New compounds, their preparation and use |
| 08/16/2001 | EP1123296A1 PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION |
| 08/16/2001 | EP1123292A1 New compounds, their preparation and use |
| 08/16/2001 | EP1123285A1 Substituted benzopyran analogs for the treatment of inflammation |
| 08/16/2001 | EP1123283A1 Thiazole-derivatives |
| 08/16/2001 | EP1123280A1 Serine protease inhibitor |
| 08/16/2001 | EP1123277A1 Epibatidine analogues as acetylcholine receptor antagonists |
| 08/16/2001 | EP1123274A1 Substituted phenyl derivatives, their preparation and use |
| 08/16/2001 | EP1123269A1 New compounds, their preparation and use |
| 08/16/2001 | EP1123120A1 Medicinal aerosol formulation |
| 08/16/2001 | EP1123115A1 Treatment of trauma (ie graft rejection) with liposomes containing dna encoding for ctla4ig or for anti cd40l |
| 08/16/2001 | EP1123113A1 Ribozymes used as prodrugs |
| 08/16/2001 | EP1123110A1 Compositions and methods for promoting tissue repair using heat shock proteins |
| 08/16/2001 | EP1123109A1 Contulakin-g, analogs thereof and uses therefor |
| 08/16/2001 | EP1123096A1 Bioflavonoids as plasma high density lipoprotein level increasing agent |
| 08/16/2001 | EP1123094A1 Therapeutic compositions (ii) |
| 08/16/2001 | EP1123091A1 Combination product comprising an e-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use |
| 08/16/2001 | EP1123090A1 Method and composition for modulating amyloidosis |
| 08/16/2001 | EP1123088A1 Controlled-release pharmaceutical formulations containing a cgmp pde-5 inhibitor |
| 08/16/2001 | EP1123085A1 O/w emulsion comprising an hydroxylated oil |
| 08/16/2001 | EP1066292A4 Metallocorrinoids as biologically compatible carriers of pharmacological agents |
| 08/16/2001 | EP1035851B1 Endothelin receptor antagonists for combating hyperlipidaemia |
| 08/16/2001 | EP0944388A4 Inhibitors of farnesyl-protein transferase |
| 08/16/2001 | EP0812199A4 Sphingosine, methylsphingosine and apoptosis |
| 08/16/2001 | EP0694307B1 Atopic disease remedy |
| 08/16/2001 | EP0649309B1 Use of particles of a biocompatible, bioabsorbable calcium salt as active principle in the preparation of a medicament for local treatment of bone demineralizing diseases |
| 08/16/2001 | EP0628042B1 Serotoninergic ergoline derivatives |
| 08/16/2001 | DE10006139A1 Indol-3-yl-Derivate Indol-3-yl derivatives |
| 08/16/2001 | DE10004858A1 Verwendung von Proteinkinase-Inhibitor-alpha The use of protein kinase inhibitor alpha- |
| 08/16/2001 | DE10004857A1 MLP-Gen, Nukleinsäuren, Polypeptide und deren Verwendung MLP-gene nucleic acids, polypeptides and their use |
| 08/16/2001 | CA2400497A1 Methods and compositions for generating angiostatin |
| 08/16/2001 | CA2400472A1 Il-17 like molecules and uses thereof |